Search Results

SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site. The investment is supported by $21 million in state and local incentive awards and will expand SCHOTT Group’s presence in the United States, a strategic market in its growth plan.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems, a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution.

SCHOTT, the international technology group and inventor of specialty glass, was among the winners of the Pharma Innovation Award for its SCHOTT TOPPAC® freeze prefillable polymer syringes.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer.

Specializing in the growing sector of Advanced Therapy Medicinal Products, the cooperation focuses its efforts on drug delivery solutions and freezing applications for cell and gene therapies.

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI).

SCHOTT continues to produce record-breaking numbers of pharmaceutical containers, including critical glass vials, as the U.S. prepares for COVID-19 vaccine distribution.

SCHOTT’s pharmaceutical packaging business unit has delivered enough vials to provide more than 1 billion doses of COVID-19 vaccines, marking a massive contribution to the global fight against COVID-19

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.